INTENSITY THERAPEUTICS, INC. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Intensity Therapeutics (market cap ~$7.4M) resumed enrollment in its Phase 3 INVINCIBLE-3 soft tissue sarcoma trial in April 2026 after a March 2025 pause due to funding constraints; the trial had enrolled 21 patients during the pause. The company restarted patient treatment in Phase 2 INVINCIBLE-4 (triple negative breast cancer) in July 2026 after protocol modifications; preliminary data from 14 patients showed 71% pathological complete response in the INT230-6 arm vs. 42% in standard-of-care alone, with 44% fewer grade 3 adverse events. Cash position: $9.5M as of June 30, 2026; raised $1.6M net in Q2 2026 under a $60M ATM facility and additional $1.3M post-quarter.
Why this rating
Trial resumption and early efficacy data materially advance pipeline; cash runway supports operations. For $7.4M market-cap company, $9.5M cash covers several quarters but raises questions about path to sustainability without partnership or further capital raises.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.